Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT +10.71% Net Cash per Share is A$-0.04 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 245 Drug Manufacturers companies, Vitura Health ranks worse than 408162.86% on this metric.
The historical rank and industry rank for Vitura Health's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of Vitura Health was 51.50. The lowest was 0.85. And the median was 1.86.
ASX:VIT's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.62 * Ranked among companies with meaningful Price-to-Net-Cash only.
Vitura Health (ASX:VIT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Vitura Health Net Cash per Share Related Terms
Vitura Health Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Vitura Health's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Vitura Health's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Vitura Health's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a Net Cash per Share of A$-0.04 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vitura Health and its competitors. According to the industry distribution chart, Vitura Health ranks #999999 out of 245 companies in the Drug Manufacturers industry.
Is Vitura Health's Net Cash per Share too high?
Vitura Health's current Net Cash per Share is A$-0.04. Based on the distribution chart, Vitura Health ranks #999999 out of 245 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Vitura Health's Net Cash per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #999999 out of 245 companies for Net Cash per Share. This places Vitura Health in the lower half of its industry. The industry median Net Cash per Share is 8.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.62, based on 245 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current Net Cash per Share is A$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.09, compared to a current price of A$0.03 — trading 65.6% below its estimated fair value. The current Net Cash per Share is A$-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current Net Cash per Share is A$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
